Publication at Faculty of Medicine in Pilsen |
2023
Abstract
Reducing the risk of febrile neutropenia and thus maintaining the relative dose intensity of chemotherapy is an important topic, especially in the adjuvant treatment of breast cancer. With the now practically common availability of pegylated granulopoiesis growth factors to ensure the prophylaxis of febrile neutropenia, the occurrence of this complication can very well be reduced.
In this way, it is possible to contribute to reducing the risk of infectious complications or the consequences of given reductions in antitumor chemotherapy.